Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 12% and 86.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
RICHMOND, Calif., May 02, 2024--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
RICHMOND, Calif., April 22, 2024--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT